Anixa Biosciences (ANIX) Retained Earnings (2010 - 2026)
Anixa Biosciences' (ANIX) quarterly Retained Earnings came in at $270.9 million in Q2 2026, up 3.21% YoY from $262.5 million in Q2 2025, and up 1.65% on a QoQ basis from $266.5 million in Q4 2025.
Anixa Biosciences (ANIX) Retained Earnings (2010 - 2026) Analysis & Trends
Anixa Biosciences (ANIX) has 17 years of Retained Earnings data on file, last reported at $270.9 million in Q2 2026.
- Quarterly Retained Earnings rose 3.21% year-over-year to $270.9 million in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $270.9 million (up 3.21% YoY) and the FY2025 annual result came in at $266.5 million, up 2.33% from the prior year.
- Retained Earnings improved to $270.9 million in Q2 2026, from $266.5 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $270.9 million in Q2 2026 to a low of $242.3 million in Q1 2022.
- A 5-year average of $255.3 million and a median of $255.7 million in 2024 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2022 — Retained Earnings climbed 16.83% — and 2025, when it advanced 1.77%.
- Tracing ANIX's Retained Earnings over 5 years: stood at $247.1 million in 2022, then advanced by 2.06% to $252.2 million in 2023, then climbed by 3.26% to $260.4 million in 2024, then advanced by 2.33% to $266.5 million in 2025, then increased by 1.65% to $270.9 million in 2026.
- The last three Retained Earnings figures came in at $270.9 million (Q2 2026), $266.5 million (Q4 2025), and $265.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 4.38 Bn |
| 10 | Anixa Biosciences | 124.96 Mn | 124.96 Mn | - | 270.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 270.89 Mn |
| Oct 31, 2025 | 266.51 Mn |
| Jul 31, 2025 | 265.25 Mn |
| Apr 30, 2025 | 262.47 Mn |
| Jan 31, 2025 | 261.47 Mn |
| Oct 31, 2024 | 260.43 Mn |
| Jul 31, 2024 | 259.32 Mn |
| Apr 30, 2024 | 257.89 Mn |
| Jan 31, 2024 | 255.74 Mn |
| Oct 31, 2023 | 252.22 Mn |
| Jul 31, 2023 | 250.72 Mn |
| Apr 30, 2023 | 249.50 Mn |
| Jan 31, 2023 | 248.19 Mn |
| Oct 31, 2022 | 247.12 Mn |
| Jul 31, 2022 | 246.30 Mn |
| Apr 30, 2022 | 244.03 Mn |
| Jan 31, 2022 | 242.28 Mn |
| Oct 31, 2021 | 239.93 Mn |
| Jul 31, 2021 | 236.94 Mn |
| Apr 30, 2021 | 233.74 Mn |